B of A Securities Maintains Buy on Insmed, Raises Price Target to $213

B of A Securities analyst Jason Zemansky has maintained a Buy rating on Insmed (NASDAQ: INSM) and raised the price target from $211 to $213. This adjustment reflects a positive outlook for the company's stock.